Literature DB >> 23414988

Lung cancer lymph node micrometastasis detection using real-time polymerase chain reaction: correlation with vascular endothelial growth factor expression.

Chukwumere E Nwogu1, Sai Yendamuri, Wei Tan, Eric Kannisto, Paul Bogner, Carl Morrison, Richard Cheney, Elisabeth Dexter, Anthony Picone, Mark Hennon, Alan Hutson, Mary Reid, Alex Adjei, Todd L Demmy.   

Abstract

OBJECTIVES: Lymph node staging provides critical information in patients with non-small cell lung cancer (NSCLC). Lymphangiogenesis may be an important contributor to the pathophysiology of lymphatic metastases. We hypothesized that the presence of lymph node micrometastases positively correlates with vascular endothelial growth factors (VEGFs) A, C, and D as well as VEGF-receptor-3 (lymphangiogenic factors) expression in lymph nodes.
METHODS: Forty patients with NSCLC underwent preoperative positron emission tomography-computed tomography and mediastinoscopy. Real-time polymerase chain reaction (RT-PCR) assays for messenger RNA expression of epithelial markers (ie, cytokeratin 7; carcinoembryonic antigen-related cell adhesion molecule 5; and palate, lung, and nasal epithelium carcinoma-associated protein) were performed in selected fluorodeoxyglucose-avid lymph nodes. VEGF-A, VEGF-C, VEGF-D, and VEGF receptor-3 expression levels were measured in primary tumors and lymph nodes. Wilcoxon rank sum test was run for the association between the RT-PCR epithelial marker levels and VEGF expression levels in the lymph nodes.
RESULTS: RT-PCR for cytokeratin 7; carcinoembryonic antigen-related cell adhesion molecule 5; or palate, lung, and nasal epithelium carcinoma-associated protein indicated lymph node micrometastatic disease in 19 of 35 patients (54%). There was a high correlation between detection of micrometastases and VEGF-A, VEGF-C, VEGF-D, or VEGF receptor-3 expression levels in lymph nodes. Median follow-up was 12.6 months.
CONCLUSIONS: RT-PCR analysis of fluorodeoxyglucose-avid lymph nodes results in up-staging a patient's cancer. Micrometastases correlate with the expression of VEGF in lymph nodes in patients with NSCLC. This may reflect the role of lymphangiogenesis in promoting metastases.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23414988      PMCID: PMC3584695          DOI: 10.1016/j.jtcvs.2012.12.023

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  23 in total

1.  Staging of regional nodes in pulmonary malignancies.

Authors:  Mark B Faries; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2012-03       Impact factor: 5.344

2.  Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival.

Authors:  Chun-Dong Gu; Toshihiro Osaki; Tsunehiro Oyama; Masaaki Inoue; Mantaro Kodate; Kazuhito Dobashi; Takeshi Oka; Kosei Yasumoto
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

3.  Immunohistochemically detected micrometastases in peribronchial and mediastinal lymph nodes from patients with T1, N0, M0 pulmonary adenocarcinomas.

Authors:  N S Goldstein; A Mani; G Chmielewski; R Welsh; S Pursel
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

4.  Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases.

Authors:  T Hashimoto; Y Kobayashi; Y Ishikawa; S Tsuchiya; S Okumura; K Nakagawa; Y Tokuchi; M Hayashi; K Nishida; S Hayashi; J Hayashi; E Tsuchiya
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

Review 5.  Sentinel node and positron emission tomography mapping in lung cancer.

Authors:  Chukwumere Nwogu
Journal:  Semin Thorac Cardiovasc Surg       Date:  2009

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

7.  Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer.

Authors:  M J Liptay; G A Masters; D J Winchester; B L Edelman; B J Garrido; T R Hirschtritt; R M Perlman; W A Fry
Journal:  Ann Thorac Surg       Date:  2000-08       Impact factor: 4.330

8.  Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases.

Authors:  S Benlloch; J M Galbis-Caravajal; C Alenda; F M Peiró; M Sanchez-Ronco; J M Rodríguez-Paniagua; B Baschwitz; E Rojas; B Massutí
Journal:  Ann Oncol       Date:  2008-07-29       Impact factor: 32.976

9.  Bronchoscopic radioisotope injection for sentinel lymph-node mapping in potentially resectable non-small-cell lung cancer.

Authors:  D Lardinois; T Brack; A Gaspert; T Spahr; D Schneiter; H C Steinert; W Weder
Journal:  Eur J Cardiothorac Surg       Date:  2003-05       Impact factor: 4.191

Review 10.  Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology.

Authors:  Xiaolong Jiao; Mark J Krasna
Journal:  Ann Thorac Surg       Date:  2002-07       Impact factor: 4.330

View more
  9 in total

1.  Clinical value of nodal micrometastases in patients with non-small cell lung cancer: time for reconsideration?

Authors:  Angelo Carretta
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

2.  Prediction Model for Nodal Disease Among Patients With Non-Small Cell Lung Cancer.

Authors:  Francys C Verdial; David K Madtes; Billanna Hwang; Michael S Mulligan; Katherine Odem-Davis; Rachel Waworuntu; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2019-01-30       Impact factor: 4.330

3.  Unless I see, I will not believe.

Authors:  Pietro Bertoglio; Stéphane Renaud; Francesco Guerrera
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 4.  Current innovations in sentinel lymph node mapping for the staging and treatment of resectable lung cancer.

Authors:  Krista J Hachey; Yolonda L Colson
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

5.  Positive expression of pro-opiomelanocortin (POMC) is a novel independent poor prognostic marker in surgically resected non-small cell lung cancer.

Authors:  Ligang Hao; Xiaoliang Zhao; Bin Zhang; Chenguang Li; Changli Wang
Journal:  Tumour Biol       Date:  2014-11-07

6.  Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer.

Authors:  Farhood Farjah; David K Madtes; Douglas E Wood; David R Flum; Megan E Zadworny; Rachel Waworuntu; Billanna Hwang; Michael S Mulligan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-06       Impact factor: 5.209

7.  Detection of occult tumor cells in regional lymph nodes is associated with poor survival in pN0 non-small cell lung cancer: a meta-analysis.

Authors:  Zhicheng He; Yang Xia; Shaowen Tang; Yijiang Chen; Liang Chen
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

8.  A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities.

Authors:  Youzhi Xu; Wenjie Lu; Peng Yang; Wen Peng; Chunting Wang; Manli Li; Yan Li; Guobo Li; Nana Meng; Hongjun Lin; Lixin Kan; Siying Wang; Shengyong Yang; Luoting Yu; YingLan Zhao
Journal:  BMC Cancer       Date:  2015-07-18       Impact factor: 4.430

Review 9.  Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.

Authors:  Thomas K Kilvaer; Erna-Elise Paulsen; Sigurd M Hald; Tom Wilsgaard; Roy M Bremnes; Lill-Tove Busund; Tom Donnem
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.